Replies to post #9410 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Found an interesting post on yahoo, unknown if the person actually worked with GVAX. But he states he has worked with GVAX and that it is superior to Provenge. But that GVAX approval would be a decade away. Jeff counters that with the 4 orphan drugs in Biosante's lineup. Trial and if successful approval would be fast tracked from 1 to 2 years. The people that need don't have the luxury of time. Note: From examining Jeff previous posts he appears very well informed.

Yahoo post

If both of these statements are true. It would greatly benefit the stock price. Denreon has only one product, Provenge and a small pipeline yet the company has $2.15 billion Market cap. Could make for interesting times.

[Just the facts maam]

This is mostly for those new to BPAX. I have tried to keep my posts based on factual information and analysis that I found. I have attached the post I have added to this board to simplify your education process. Please note the information is accurate to the date it was posted so some dollar values will change as the share price changes I am a value investor not a day trader. So if you are looking for charts you will not find any.

BPAX Fact Based Information

Hope it helps